Biotransplant(BTRN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN)

BTRN 35.47

0.0%

Dec 9 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (454)	12/7/1999 9:48:00 AM
From: scaram(o)uche	Read Replies (3) of 1475

biz.yahoo.com "...... The clinical results reported here demonstrated striking anti-tumor responses in patients with chemotherapy refractory cancer, often in the absence of graft-versus-host disease.'' >> MGH researchers reported advances in the use of a non-myeloablative conditioning regimen to achieve a strong anti-cancer response. The lack of a requirement for permanent chimerism for long-term acceptance of an organ graft in a recipient of a bone marrow and kidney graft from the same donor has been clinically demonstrated. <<

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next